Morgan Stanley analyst Judah Frommer lowered the firm’s price target on 4D Molecular (FDMT) to $6 from $8 and keeps an Underweight rating on the ...

Weiss Ratings restated their sell (d-) rating on shares of 4D Molecular Therapeutics (NASDAQ:FDMT – Free Report) in a report ...

Analyst Judah Frommer of Morgan Stanley assigned a Sell rating on 4D Molecular Therapeutics (FDMT – Research Report), with a price target of ...

In a report released today, Matthew Caufield from H.C. Wainwright reiterated a Buy rating on 4D Molecular Therapeutics (FDMT – Research ...

D Molecular Therapeutics (NASDAQ:FDMT – Get Free Report)‘s stock had its “buy” rating restated by stock analysts at HC ...

5 analysts have expressed a variety of opinions on 4D Molecular Therapeutics (NASDAQ:FDMT) over the past quarter, offering a diverse set of opinions from bullish to bearish. The table below ...

Providing a diverse range of perspectives from bullish to bearish, 6 analysts have published ratings on 4D Molecular Therapeutics (NASDAQ:FDMT) in the last three months. Summarizing their recent ...

4D Molecular Therapeutics (NASDAQ:FDMT) and the U.S. FDA have reached agreement on a phase 3 trial design for diabetic macular edema (DME) candidate 4D-150. The company will only have to conduct a ...

On Wednesday, Goldman Sachs reinstated coverage on 4D Molecular Therapeutics (NASDAQ:FDMT), assigning a Buy rating and a price target of $81.00. This move marks a shift from their ...

Positron is committed to expanding the cardiac and oncology PET modality by delivering the best technology and value to ...

4DMT operates as a clinical-stage genetic medicines company focused on inventing and developing genetic medicines to treat large market diseases in ophthalmology, pulmonology and cardiology.